Core Insights - The U.S. cannabis market is evolving with legislative discussions, consumer trends, and business developments shaping its momentum, leading to increased investor interest in companies showing signs of stabilization and long-term growth potential [1][12] - November 2025 highlights several cannabis companies that are focusing on profitability, product line expansion, and positioning for future U.S. federal reform, despite ongoing market volatility [1][12] Company Summaries Tilray Brands Inc. (TLRY) - Tilray is a global cannabis lifestyle and consumer goods company with a significant presence in North America, expanding into beverages and wellness products, which strengthens its distribution footprint [2][4] - The company reported noticeable revenue growth year-over-year, driven by stronger consumer adoption and improved product placement, although it still operates at a net loss due to restructuring and long-term investments [5][4] - Tilray's diversification strategy provides stability during slower periods in the cannabis cycle, making it a notable candidate for investment in November [5][12] Canopy Growth Corporation (CGC) - Canopy Growth is a recognized name in the cannabis sector, repositioning itself for future U.S. opportunities through a leaner operational model and strategic pathways into the American market [6][8] - The company has shown modest revenue improvement alongside significant cost reductions, with year-over-year growth in both medical and adult-use markets [8][6] - Canopy's focus on operational discipline and strategic realignment positions it well for potential benefits if regulatory conditions shift [8][12] Cronos Group Inc. (CRON) - Cronos operates as a global cannabis and cannabinoid-innovation company, focusing on premium branded products and international expansion rather than a wide footprint of U.S. dispensaries [9][11] - The company has demonstrated solid revenue growth, reflecting rising consumer demand, although it operates at a loss due to research spending and expansion efforts [11][9] - Cronos maintains a strong cash position relative to its size, providing flexibility during uncertain periods, making it an appealing option for investors seeking growth potential beyond direct U.S. retail expansion [11][12]

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a moderate growth ranking despite weaker trends across all timeframes, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which viewed the hemp-derived product segment as a key entry point into the U.S. market [8].

Four cannabis stocks are demonstrating significant technical momentum, seemingly undeterred by new regulatory headwinds from Washington.Momentum Improves For 4 Cannabis StocksThe positive trend comes even as Congress passed a government funding bill that includes a controversial provision to re-criminalize many popular hemp-derived THC products, a move that could disrupt a large segment of the market.The stocks logging the gains include Tilray Brands Inc. (NASDAQ:TLRY) , Cronos Group Inc. (NASDAQ:CRON) , Or ...

In this articleCRON-CACRONCURA-CAwatch nowThe hemp industry is bracing for layoffs, production reductions and billions in lost revenue after Congress passed a government funding bill late Wednesday containing a surprise provision that will ban nearly all hemp-derived consumer products.Hemp, a derivative of the cannabis plant, was legalized in the 2018 Farm Bill for industrial uses like rope, textiles and seed. But the law's broad definition created a loophole in federal rules on THC — the psychoactive compo ...

 November 13, 2025 – TheNewswire - Vancouver, British Columbia - Arcus Development Group Inc. (TSXV:ADG.H)(“Arcus”) announces that further to its news release of November 4, 2025 and October 15, 2025, it will increase the size of its ongoing private place up to a maximum of $1,650,000.  Subject to TSX Venture Exchange acceptance, the increased financing will close concurrently with an Arcus share consolidation, as described below:  (i)        immediately prior to the closing of the financing, Arcus will co ...

Financial Data and Key Metrics Changes - The company reported consolidated net revenue of $36.3 million, a 6% increase year over year, driven by higher cannabis flower sales in Israel and higher cannabis extract sales in Canada, partially offset by a decrease in cannabis flower sales in Canada [11] - Gross profit and adjusted gross profit in Q3 were $18.3 million, equating to a 50% gross margin, a 19 percentage point improvement from 31% adjusted gross margins in Q3 2024 [11] - Adjusted EBITDA in Q3 was $5.7 million, an improvement of $11.7 million year-over-year, driven by higher gross profit and lower operating expenses [12] Business Line Data and Key Metrics Changes - In Canada, flower supply constraints led to softer flower revenue year over year, but this was offset by strong performance in edibles and significant growth in the vape category [4] - The Spinach brand ended the quarter as the number two cannabis brand in Canada with 4.5% overall market share, ranking fourth in flower with 4.9% share and third in vapes with 7% share [5] - In edibles, Spinach held the number one position with 19.7% market share, and within gummies, it led the market with 22.8% share [6] Market Data and Key Metrics Changes - In Israel, Cronos Group achieved record net revenue, with Peace Naturals being the number one medical cannabis brand, driven by strong demand for flagship strains [8] - The medical patient count in Israel has returned to growth in 2025, up nearly 5% year to date [9] - International market results were lighter this quarter due to shipment timing, with expectations for the second half of 2025 net revenue to be similar to the first half [9] Company Strategy and Development Direction - The company remains focused on delivering top-line growth, margin expansion, and disciplined cost management while strengthening operations for sustainable profitability [4] - The completion of the phase two expansion at GrowCo is expected to improve flower sales in 2026, resolving supply constraints [5] - Cronos Group maintains a strong balance sheet with no debt and $824 million in cash, providing flexibility for growth and innovation [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and highlighted the strong performance of core business segments, anticipating continued growth into 2026 [15] - The company is optimistic about the impact of the Groco expansion on revenue and margins, with expectations for improved capacity utilization over time [17][19] Other Important Information - The company launched new products, including limited-edition seasonal offerings and new strains in Israel, to maintain consumer engagement and retail momentum [7][8] - The company is monitoring potential regulatory changes in Germany that could affect future market dynamics [9] Q&A Session Summary Question: Did any sales from Groco expansion occur in Q3, and what is the expected growth magnitude for 2026? - Management indicated that sales from Groco would gradually show up, with a 70% capacity increase on flower expected to impact revenue positively in 2026 [17] Question: Will underlying gross margins improve with the new Groco capacity? - Management confirmed that increased fixed cost absorption from the new facility could lead to improved margins in the future [18] Question: How much did flower supply constraints impact Q3, and what about shipment timing for international markets? - Management acknowledged that flower supply constraints weighed down performance, and shipment timing shifts would normalize, making the second half of the year similar to the first half [20][21]

Regulatory and Operational Challenges - The company is undergoing a public investigation related to alleged dumping of medical cannabis imports into Israel, which may impact operations and costs associated with anti-dumping duties [124]. - The company is navigating regulatory challenges related to cannabis legalization in various jurisdictions, which may impact market opportunities [126]. Cost Management and Operational Efficiency - The company has announced cost-cutting measures, including winding down operations at the Winnipeg facility, which is expected to yield significant cost savings [124]. - The company is realigning its operations to improve efficiency and reduce costs, with ongoing assessments of employee turnover and operational metrics [126]. - The company is exploring joint ventures and strategic alliances to improve revenue and operational efficiencies [124]. - The company is committed to expanding its Stayner, Ontario facility to enhance production capabilities [126]. Financial Performance - For the three months ended September 30, 2025, consolidated net revenue was $36.3 million, a 6% increase from $34.3 million in the same period of 2024 [138]. - For the nine months ended September 30, 2025, consolidated net revenue reached $102.1 million, representing a 17% increase from $87.3 million in the same period of 2024 [138]. - Gross profit for the three months ended September 30, 2025, was $18.3 million, a significant increase of 408% from $3.6 million in the same period of 2024 [141]. - Gross profit for the nine months ended September 30, 2025, was $46.6 million, an increase of 224% from $14.4 million in the same period of 2024 [141]. - Consolidated cost of sales for the three months ended September 30, 2025, was $17.5 million, a decrease of 42% from $30.3 million in the same period of 2024 [139]. - Total operating expenses for the three months ended September 30, 2025, were $18.8 million, a 49% decrease from $37.3 million in the same period of 2024 [142]. - The improvement in net income and Adjusted EBITDA was primarily due to higher gross profit and lower operating expenses, particularly a decline in general and administrative costs [174]. Income and Adjusted Metrics - For the three months ended September 30, 2025, net income was $28.3 million, an increase from $7.3 million for the same period in 2024 [164]. - For the nine months ended September 30, 2025, net loss was $2.4 million, an improvement from a net loss of $3.9 million for the same period in 2024 [164]. - Adjusted EBITDA for the three months ended September 30, 2025, was $5.7 million, representing an improvement of $11.7 million from the same period in 2024 [174]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $9.7 million, an improvement of $37.4 million from the same period in 2024 [174]. Cash Flow and Investments - Cash and cash equivalents as of September 30, 2025, were $784.2 million, a 9% decrease from $858.8 million as of December 31, 2024 [180]. - The company generated $14.0 million of cash from operating activities during the nine months ended September 30, 2025, compared to $11.1 million in the same period in 2024, representing an increase of $2.9 million [188]. - Cash used in investing activities during the nine months ended September 30, 2025, was $79.3 million, a change of $259.5 million compared to cash provided by investing activities in the same period in 2024 [189]. - Cash used in financing activities was $12.5 million during the nine months ended September 30, 2025, compared to $0.9 million in the same period in 2024, representing an increase of $11.6 million [190]. - The company authorized a share repurchase program of up to $50.0 million, with 917,862 shares repurchased in the three months ended September 30, 2025 [191].

Exhibit 99.1 Cronos Group Reports 2025 Third Quarter Results Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA Net revenue in Q3 2025 increased by 9% quarter-over-quarter and 6% year-over-year Generated record-high net revenue in Israel, where PEACE NATURALS remains the number one cannabis brand ® 1 Industry-leading balance sheet with $824 million in total cash and cash equivalents and short-term investments TORONTO, November 6, 2025 - Cronos Group Inc. (NASDAQ: CRON) (TSX ...

Core Insights - Cronos Group Inc. achieved record levels of consolidated net revenue, gross profit, and Adjusted EBITDA in Q3 2025, with net revenue increasing by 9% quarter-over-quarter and 6% year-over-year [1][2] - The company reported record-high net revenue in Israel, where its PEACE NATURALS brand remains the number one cannabis brand [1][2] - Cronos Group maintains a strong balance sheet with $824 million in total cash and cash equivalents and short-term investments [1][3] Financial Performance - Net revenue for Q3 2025 was $36.3 million, an increase of $2.1 million from Q3 2024, primarily driven by higher cannabis flower sales in Israel and cannabis extract sales in Canada [10] - Gross profit for Q3 2025 was $18.3 million, up $14.7 million from Q3 2024, attributed to lower inventory step-up costs and higher average sales prices [10][7] - Adjusted EBITDA improved to $5.7 million in Q3 2025, an increase of $11.7 million from Q3 2024, driven by higher gross profit and lower operating expenses [10][7] Market Position - The Spinach brand ended Q3 2025 as the second most popular brand in Canada, holding a 4.5% total market share, and ranked 1 in edibles with a 19.7% market share [11][12] - PEACE NATURALS continues to be the top-performing brand in Israel, achieving record net revenue and sales volume in Q3 2025 [15][16] - International results outside of Israel were modest due to shipment timing, with expectations for second-half performance to align closely with the first half [16] Brand and Product Updates - The Spinach brand launched new products, including SOURZ by Spinach Fully Blasted gummies and limited-edition flavors, reinforcing its leadership in innovative cannabis edibles [12] - Cronos Group's expansion of Cronos GrowCo is complete, with sales from the expansion expected to fuel growth in 2026 [17] - The company introduced new strains under the PEACE NATURALS brand in Israel, reflecting its advanced genetic breeding program and cultivation capabilities [15]

Core Insights - The Canadian cannabis market is evolving with global demand increasing and U.S. legalization being a significant topic of interest [1][13] - Major producers are focusing on profitability, cost reduction, and high-margin opportunities like medical exports and branded products [1][13] Company Summaries Tilray Brands, Inc. (TLRY) - Tilray is expanding its U.S. presence through hemp-derived THC beverages and wellness products, focusing on consumer engagement and product innovation [3][5] - For fiscal 2025, Tilray's total net revenue increased by approximately 4% year over year to over $820 million, with gross profit in its cannabis division rising to nearly $100 million and gross margin expanding from 33% to 40% [5][12] - Despite facing a net loss due to impairment charges, management is confident in its restructuring plan and international expansion strategy [5][12] Cronos Group Inc. (CRON) - Cronos is focused on innovation and cannabinoid research, preparing for potential federal legalization in the U.S. while serving international medical and wellness markets [7][9] - In 2024, Cronos's annual net revenue rose by over 30%, with quarterly results in early 2025 showing continued progress and net income turning positive for the first time in years [9][12] - The company maintains a strong balance sheet with substantial cash reserves and minimal debt, positioning itself for sustained growth [9][12] Aurora Cannabis Inc. (ACB) - Aurora serves both medical and recreational markets across more than 25 countries, focusing on medical exports and high-quality production [10][12] - The company reported over 35% year-over-year revenue growth in 2025, with medical cannabis sales rising over 50% [12] - Aurora's strategic pivot towards the higher-margin medical market has improved profitability and stabilized cash flow, positioning it well for future growth [12][13] Industry Outlook - The Canadian cannabis sector is navigating a critical transformation period, with companies like Tilray, Cronos, and Aurora leading the charge [13][14] - Investors are encouraged to monitor technical patterns and apply strict risk management to capitalize on potential growth opportunities in November 2025 [14]